ANTIHYPERTENSIVE TREATMENT WITH FELODIPINE BUT NOT WITH A DIURETIC REDUCES EPISODES OF MYOCARDIAL-ISCHEMIA IN ELDERLY PATIENTS WITH HYPERTENSION

被引:17
|
作者
TRENKWALDER, P
DOBRINDT, R
AULEHNER, R
LYDTIN, H
机构
[1] Department of Internal Medicine, Starnberg Hospital, Ludwig Maximilian University Munich Teaching Hospital, Starnberg
关键词
HYPERTENSION; TRANSIENT MYOCARDIAL ISCHEMIA; ST-SEGMENT DEPRESSION; CALCIUM ANTAGONISTS; DIURETICS; BLOOD PRESSURE;
D O I
10.1093/oxfordjournals.eurheartj.a060451
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Episodes of transient myocardial ischaemia can frequently be observed in hypertensive patients. To assess the effects of antihypertensive treatment with the calcium antagonist felodipine or the diuretic combination hydrochlorothiazidel triamterene on episodes of ischaemic-type ST-segment depression (ST-D), simultaneous ambulatory electrocardiographic and blood pressure (BP) monitoring was performed in 42 elderly hypertensives without manifest coronary artery disease. All patients (mean age 79 +/- 6 years, office BP greater-than-or-equal-to 160/95 mmHg) were evaluated off any antihypertensive or anti-ischaemic therapy and after 3 months treatment with either felodipine or the diuretic (randomized, double-blind study) for episodes of significant ST-D (greater-than-or-equal-to 0.1 mV, duration greater-than-or-equal-to 1 min, interval greater-than-or-equal-to 1 min). The reduction in office BP and daytime ambulatory BP was similar for both agents, as was a significant reduction in the heart rate x systolic BP product (DP) over 24 h (felodipine: 12 441 +/- 2076 vs 11 643 +/- 1953 mmHg.min-1; P=0.048; diuretic: 12 366 +/- 2782 vs 11 062 +/- 2012 mmHg.min-1; P=0.03). While felodipine significantly decreased the total number of ST-D (from 40 to six episodes; P=0.03), the total number of ST-D remained unchanged with the diuretic (non-significant increase from 31 to 45 episodes; P=0.24). The same trend was observed for the number of patients with ST-D. The ischaemic threshold, defined as DP at the onset of the episodes of ST-D, increased with felodipine (12 171 +/- 340 vs 13 770 +/- 138 mmHg.min-1) and decreased with the diuretic (16 210 +/- 312 vs 14 092 +/- 319 mmHg.min-1). In conclusion, antihypertensive treatment with felodipine reduces blood pressure and episodes of transient myocardial ischaemia in elderly hypertensive patients, while hydrochlorothiazide/triamterene increases these episodes despite a similar BP reduction. Felodipine may influence structural and functional factors at the coronary microcirculation level. These mechanisms improve coronary blood flow and increase the ischaemic threshold.
引用
收藏
页码:1673 / 1680
页数:8
相关论文
共 50 条
  • [31] Amlodipine, felodipine, and isradipine in the treatment of Chinese patients with mild-to-moderate hypertension
    Cheung, BMY
    Lau, CP
    Wu, BZ
    CLINICAL THERAPEUTICS, 1998, 20 (06) : 1159 - 1169
  • [32] The Optimal Target Blood Pressure for Antihypertensive Treatment in Japanese Elderly Patients with High-Risk Hypertension: A Subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial
    Ogihara, Toshio
    Nakao, Kazuwa
    Fukui, Tsuguya
    Fukiyama, Kohshiro
    Fujimoto, Akira
    Ueshima, Kenji
    Oba, Koji
    Shimamoto, Kazuaki
    Matsuoka, Hiroaki
    Saruta, Takao
    HYPERTENSION RESEARCH, 2008, 31 (08) : 1595 - 1601
  • [33] The Optimal Target Blood Pressure for Antihypertensive Treatment in Japanese Elderly Patients with High-Risk Hypertension: A Subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial
    Toshio Ogihara
    Kazuwa Nakao
    Tsuguya Fukui
    Kohshiro Fukiyama
    Akira Fujimoto
    Kenji Ueshima
    Koji Oba
    Kazuaki Shimamoto
    Hiroaki Matsuoka
    Takao Saruta
    Hypertension Research, 2008, 31 : 1595 - 1601
  • [34] Antihypertensive treatment using an angiotensin receptor blocker and a thiazide diuretic improves patients' quality of life: The Saga Challenge Antihypertensive Study (S-CATS)
    Kamura, Aoi
    Inoue, Teruo
    Kuroki, Shigetaka
    Ishida, Shiro
    Iimori, Kenichirou
    Kato, Toru
    Naitoh, Hirofumi
    Tamesue, Satoshi
    Ikeda, Hideo
    Node, Koichi
    HYPERTENSION RESEARCH, 2011, 34 (12) : 1288 - 1294
  • [35] COMPARISON AND INTERACTION OF LOW-DOSE FELODIPINE AND ENALAPRIL IN THE TREATMENT OF ESSENTIAL-HYPERTENSION IN ELDERLY SUBJECTS
    MORGAN, TO
    ANDERSON, A
    JONES, E
    AMERICAN JOURNAL OF HYPERTENSION, 1992, 5 (04) : 238 - 243
  • [36] Long-term evaluation of combined antihypertensive therapy with lisinopril and a thiazide diuretic in patients with essential hypertension
    Ishimitsu, T
    Yagi, S
    Ebihara, A
    Doi, Y
    Domae, A
    Shibata, A
    Kimura, M
    Sugishita, Y
    Sagara, E
    Sakamaki, T
    Murata, K
    JAPANESE HEART JOURNAL, 1997, 38 (06): : 831 - 840
  • [37] WHY IS ANTIHYPERTENSIVE DRUG-THERAPY NEEDED IN ELDERLY PATIENTS WITH SYSTOLODIASTOLIC HYPERTENSION
    THIJS, L
    FAGARD, R
    LIJNEN, P
    STAESSEN, J
    VANHOOF, R
    AMERY, A
    JOURNAL OF HYPERTENSION, 1994, 12 : S25 - S34
  • [38] Risk factors for silent myocardial ischemia in patients with well-controlled essential hypertension
    Rendina, Domenico
    Ippolito, Renato
    De Filippo, Gianpaolo
    Muscariello, Riccardo
    De Palma, Daniela
    De Bonis, Silvana
    di Cola, Michele Schiano
    Benvenuto, Domenico
    Galderisi, Maurizio
    Strazzullo, Pasquale
    Galletti, Ferruccio
    INTERNAL AND EMERGENCY MEDICINE, 2017, 12 (02) : 171 - 179
  • [39] Comparison of monotherapy versus combination antihypertensive therapy in elderly patients with essential hypertension
    Antonopoulos, Stavros
    Kokkoris, Stelios
    Gerakari, Styliani
    Mikros, Sotirios
    Nitsotolis, Thomas
    Vikeli, Despina
    Korantzopoulos, Panagiotis
    Giannoulis, Gregory
    ANGIOLOGY, 2008, 59 (02) : 230 - 235
  • [40] Metabolic effects of combined antihypertensive treatment in patients with essential hypertension
    Quiñones-Galvan, A
    Pucciarelli, A
    Ciociaro, D
    Masoni, A
    Franzoni, F
    Natali, A
    Ferrannini, E
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2002, 40 (06) : 916 - 921